RT Journal Article
SR Electronic
T1 Reactogenicity and immunogenicity against MPXV of the intradermal administration of Modified Vaccinia Ankara compared to the standard subcutaneous route
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.17.24313609
DO 10.1101/2024.09.17.24313609
A1 Mazzotta, Valentina
A1 Piselli, Pierluca
A1 Lepri, Alessandro Cozzi
A1 Matusali, Giulia
A1 Cimini, Eleonora
A1 Esvan, Rozenn
A1 Colavita, Francesca
A1 Gagliardini, Roberta
A1 Notari, Stefania
A1 Oliva, Alessandra
A1 Meschi, Silvia
A1 Casetti, Rita
A1 Micheli, Giulia
A1 Bordi, Licia
A1 Giacinta, Alessandro
A1 Grassi, Germana
A1 Tekle, Saba Gebremeskel
A1 Cimaglia, Claudia
A1 Paulicelli, Jessica
A1 Caioli, Alessandro
A1 Gallì, Paola
A1 Duca, Giulia Del
A1 Lichtner, Miriam
A1 Sarmati, Loredana
A1 Tamburrini, Enrica
A1 Mastroianni, Claudio
A1 Latini, Alessandra
A1 Faccendini, Paolo
A1 Fontana, Carla
A1 Nicastri, Emauele
A1 Siddu, Andrea
A1 Barca, Alessandra
A1 Vaia, Francesco
A1 Girardi, Enrico
A1 Maggi, Fabrizio
A1 Antinori, Andrea
A1 MPOX Vaccine Lazio Study Group
YR 2024
UL http://medrxiv.org/content/early/2024/09/18/2024.09.17.24313609.abstract
AB The recent resurgence of Mpox in central Africa has been declared again a Public Health Emergency of International Concern (PHEIC) requiring coordinated international responses. Vaccination is a priority to expand protection and enhance control strategies, but the vaccine’s need exceeds the currently available doses. Intradermal administration of one-fifth of the standard Modified-Vaccinia-Ankara (MVA-BN) dose was temporarily authorized during the 2022 PHEIC. Studies conducted before 2022 provided evidence about the humoral response against the Vaccinia virus (VACV) after vaccination but not against the Mpox virus (MPXV). Moreover, no data are available on the T-cell response elicited by MVA-BN administered subcutaneously or intradermally. Here, we compare the two vaccine administration routes according to reactogenicity and immunogenicity based on data from 943 vaccine recipients during the 2022 vaccination campaign in Rome, Italy. We found that the intradermal route elicited slightly higher titers of MPXV-specific IgG and nAbs than the subcutaneous one. At the same time, no differences in cellular response were detected. MVA-BN was globally well tolerated despite higher reactogenicity for the intradermal than the subcutaneous route, especially for the reactions at the local injection site. The intradermal dose-sparing strategy was proven safe and immunogenic and would make vaccination available to more people.Competing Interest StatementAA received a grant from Bavarian Nordic for participation in conferences. The other authors declared no conflicts of interest.Funding StatementThe study was supported by the National Institute for Infectious Disease Lazzaro Spallanzani <IRCCS Advanced grant 5x1000, 2021> and by the Italian Ministry of Health <Ricerca Corrente Linea 2> INMI Spallanzani IRCCSAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The INMI Lazzaro Spallanzani Ethical Committee gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData are available upon reasonable request from the corresponding author.